Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic acid mesotherapy for melasma
NCT04170088Phase 3Completed
- Sponsor
- Jinnah Postgraduate Medical Centre
- Start
- Sep 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of tranexamic acid in melasma (2 arms), sponsored by Jinnah Postgraduate Medical Centre. Primary endpoint: Modified Melasma Area and Severity Index at 10 months. Started Sep 2018; status: completed.
02
Drugs
tranexamic acid
03
Conditions
melasma
Beyond the preview
Go deeper on NCT04170088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04170088.